Skip to main content
HR 6376 110th Congress House Health Access to health care Animals Bribery Commerce Congress Congressional reporting requirements Conspiracy Crime and Law Enforcement Drug approvals Drug industry Drugs Extortion Fines (Penalties) Fraud Law Medical supplies Obstruction of justice Organized crime Perjury

Strengthening of FDA Integrity Act of 2008

Introduced: June 26, 2008 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 26, 2008
Referred to the Subcommittee on Health.
Jun 26, 2008
Referred to the House Committee on Energy and Commerce.
Jun 26, 2008
Introduced in House
 Plain-English summary Congressional Research Service

Strengthening of FDA Integrity Act of 2008 - Amends the Federal Food, Drug, and Cosmetic Act to apply debarment provisions currently applicable to abbreviated new drugs to any drug products, including new drugs, animal drugs, exported drugs, biological products, and medical devices.

Expands the conditions under which persons (i.e., partnerships, corporations, and associations) are subject to mandatory and permissive debarment preventing such persons from submitting an application for approval of a drug product.

Requires the Secretary of Health and Human Services, in determining the appropriateness and the period of debarment, to consider whether debarment will affect the public health because sufficient quantities of the drug would not be available.

Requires the Secretary to annually report to Congress on the implementation of debarment provisions.

What's happening now June 26, 2008

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Republican 1